Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Investors can access the live webcast and archived replay on the company Events page; registered participants may receive dial-in numbers and a unique PIN to ask questions.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Offering closed | Negative | -2.4% | Closed public offering and private placement with intended R&D use. |
| Jan 30 | Offering priced | Negative | -19.4% | Priced large public offering and concurrent private placement. |
| Jan 29 | Offering announced | Negative | -19.4% | Announced proposed underwritten public offering and private placement. |
| Jan 23 | Corporate milestone | Neutral | -3.4% | Planned Nasdaq closing bell ceremony for 30th anniversary. |
| Jan 21 | Clinical update | Positive | +19.1% | FDA raised no objections to advancing pilavapadin into Phase 3. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative reactions to equity offerings and a strong positive move on favorable clinical progress, indicating sensitivity to dilution and value-creating pipeline milestones.
Over the past months, Lexicon reported multiple financing events, including public offerings and a concurrent private placement, which saw shares decline between 2.44% and 19.44%. A corporate milestone event, its 30th anniversary Nasdaq closing bell, had a modest -3.41% reaction. In contrast, a positive clinical update on pilavapadin following a successful End-of-Phase 2 FDA meeting coincided with a 19.08% gain. Against this backdrop, the newly announced Q4 2025 earnings date serves as a scheduling update rather than a value-defining catalyst by itself.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
